Skip to main content
. 2016 Nov 8;15:543. doi: 10.1186/s12936-016-1596-8

Fig. 1.

Fig. 1

Development of the MAL1C-competition ELISA. Optimal dilutions of B-MAL1C and streptavidin-HRP were defined using a checkerboard titration experiment (a). At a 1/16,000 dilution of streptavidin-HRP a sigmoidal curve was observed; this dilution was used for further experiments. B-MAL1C dilutions in the range between the maximal absorbance (plateau observed at 1/50,000) and half max (max/2 observed at 1/400,000) were explored in an inhibition set up using defined sera with high and low antibody content in R32LR ELISA assay (b) and the three monoclonal antibodies, MAL1C, MAL2A and MAL3B (c). The data shown in panels b and c were obtained with the highest serum concentrations (starting dilution 1/5) and with mAb concentrations of 5 µg/ml